On July 23, Medpace surged 22.51% in regular trading, trading at $633.125/share, with turnover of $26.74 million. The rally was driven by the company's strong Q2 financial results that comprehensively exceeded market expectations, coupled with an upward revision to full-year guidance.

Specifically, Medpace reported Q2 EPS of $4.25, beating the analyst consensus estimate of $3.97 by approximately 7%, representing a 37.1% year-over-year increase from $3.10. Revenue reached $707.3 million, up from $603.3 million a year ago, surpassing the Street estimate of $687.6 million. New business awards totaled $795.7 million, up 28.2% year-over-year, resulting in a net book-to-bill ratio of 1.13x. For full-year guidance, management expects revenue of $2.81 billion to $2.89 billion versus the FactSet estimate of $2.77 billion, and EPS of $17.25 to $17.95 versus the consensus of $16.97.

Medpace is a global leader in clinical contract research, providing Phase I through Phase IV clinical development services to the biotechnology, pharmaceutical, and medical device industries, with particular strength in oncology and metabolic diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)